Truist ups Amneal Pharmaceuticals price target, says pullback great entry point

Truist analyst Les Sulewski raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares following “solid” Q4 results. The firm told investors that while revenue guidance for FY26 is slightly below the Street, EBITDA growth guidance is the standout item. Truist added that management’s execution earns “high marks” and that it sees the stock pullback as a “great” entry point.